このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
HARP 株式概要
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Harpoon Therapeutics, Inc. 競合他社
価格と性能
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.01 |
| 52 Week High | US$23.21 |
| 52 Week Low | US$3.11 |
| Beta | 2.1 |
| 1 Month Change | 2.49% |
| 3 Month Change | 162.97% |
| 1 Year Change | 243.43% |
| 3 Year Change | -88.71% |
| 5 Year Change | -81.26% |
| Change since IPO | -82.96% |
最新ニュース
Recent updates
Improved Revenues Required Before Harpoon Therapeutics, Inc. (NASDAQ:HARP) Stock's 97% Jump Looks Justified
Jan 30
Harpoon Therapeutics, Inc. (NASDAQ:HARP) Looks Inexpensive After Falling 55% But Perhaps Not Attractive Enough
Oct 01Analysts Just Made A Notable Upgrade To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Forecasts
Aug 14Forecast: Analysts Think Harpoon Therapeutics, Inc.'s (NASDAQ:HARP) Business Prospects Have Improved Drastically
May 28Harpoon Therapeutics (NASDAQ:HARP) Will Have To Spend Its Cash Wisely
Mar 11Harpoon Therapeutics appoints Luke Walker as CMO
Oct 04Harpoon Therapeutics: A Well Undervalued Tri-Specific Oncology Player
Sep 01Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation
Jul 30Harpoon Therapeutics: A T-Cell Engager Platform And A Negative Enterprise Value Makes It A Candidate For My 'Bio Boom' Portfolio
Jul 07Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?
Mar 08We're Keeping An Eye On Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Rate
Nov 30Harpoon Therapeutics: A First Look
Sep 16Harpoon shares slide after early-stage prostate cancer study data fails to impress
Jun 04株主還元
| HARP | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | 0.2% | 0.02% | 1.2% |
| 1Y | 243.4% | 6.7% | 20.6% |
業界別リターン: HARP過去 1 年間で8.4 % の収益を上げたUS Biotechs業界を上回りました。
リターン対市場: HARP過去 1 年間で21.8 % の収益を上げたUS市場を上回りました。
価格変動
| HARP volatility | |
|---|---|
| HARP Average Weekly Movement | 32.6% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
安定した株価: HARPの株価は過去 3 か月間にわたって変動しています。
時間の経過による変動: HARPの 週次ボラティリティ は、過去 1 年間で21%から33%に増加しました。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2015 | 53 | Julie Eastland | www.harpoontx.com |
Harpoon Therapeutics, Inc. 基礎のまとめ
| HARP 基礎統計学 | |
|---|---|
| 時価総額 | US$492.35m |
| 収益（TTM） | -US$30.50m |
| 売上高(TTM) | US$37.34m |
13.2x
P/Sレシオ-16.1x
PER（株価収益率HARP は割高か？
公正価値と評価分析を参照収益と収入
| HARP 損益計算書（TTM） | |
|---|---|
| 収益 | US$37.34m |
| 売上原価 | US$58.63m |
| 売上総利益 | -US$21.29m |
| その他の費用 | US$9.21m |
| 収益 | -US$30.50m |
直近の収益報告
Sep 30, 2023
次回決算日
該当なし
| 一株当たり利益（EPS） | -1.43 |
| グロス・マージン | -57.02% |
| 純利益率 | -81.67% |
| 有利子負債／自己資本比率 | 194.4% |
HARP の長期的なパフォーマンスは？
過去の実績と比較を見る